Almirall, S.A. (LBTSF) Q3 2024 Earnings Call Transcript

Almirall, S.A. (OTCPK:LBTSF) Q3 2024 Earnings Conference Call November 11, 2024 4:00 AM ET

Company Participants

Pablo Divasson - Investor Relations
Carlos Gallardo - President & Chief Executive Officer
Karl Ziegelbauer - Chief Scientific Officer
Michael McClellan - Chief Financial Officer
Paolo Cionini - Chief Commercial Officer-Europe & International

Conference Call Participants

Lucy Codrington - Jefferies
Alistair Campbell - Royal Bank of Canada
Alvaro Lenze - Alantra Equities
Jaime Escribano - Banco Santander
Guilherme Sampaio - CaixaBank

Operator

Good day, and thank you for standing by. Welcome to the Almirall Nine Months 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference call is being recorded.

I'd like to hand the conference over to your first speaker today, Pablo Divasson. Please go ahead.

Pablo Divasson

Thank you very much, Sonia. Good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirall's 2024 nine months financial results. As always, we are showing the slides we are using today in the Investors section of our website at almirall.com.

Please move to Slide number two. Let me remind you that the information presented in this call contains forward-looking statements, which involve known and unknown risks, uncertainties and other factors that make us actual results to materially differ from what we are serving today.

Please move to Slide number three. Presenting today are Carlos Gallardo, Chairman and Chief Executive Officer; Mike McClellan, Chief Financial Officer; and Karl Ziegelbauer, Chief Scientific Officer. Carlos will start with the business highlights covering the first nine months of 2024 and will also give us an update specifically on our biologics portfolio as key growth drivers in our medical dermatology portfolio. Karl will provide you with an R&D